KR100868813B1 - 말단 분화의 유도 방법 - Google Patents
말단 분화의 유도 방법 Download PDFInfo
- Publication number
- KR100868813B1 KR100868813B1 KR1020077003262A KR20077003262A KR100868813B1 KR 100868813 B1 KR100868813 B1 KR 100868813B1 KR 1020077003262 A KR1020077003262 A KR 1020077003262A KR 20077003262 A KR20077003262 A KR 20077003262A KR 100868813 B1 KR100868813 B1 KR 100868813B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- pharmaceutical composition
- saha
- pharmaceutically acceptable
- hdac
- Prior art date
Links
- 0 *N(*)C(c(cc1)ccc1C(N(*)N)=O)=O Chemical compound *N(*)C(c(cc1)ccc1C(N(*)N)=O)=O 0.000 description 4
- BNYSWHSUCZNXLF-CCEZHUSRSA-N ONC(/C=C/c1cccc(C(C(Nc2c3ncccc3ccc2)=O)C(Nc2cccc3cccnc23)=O)c1)=O Chemical compound ONC(/C=C/c1cccc(C(C(Nc2c3ncccc3ccc2)=O)C(Nc2cccc3cccnc23)=O)c1)=O BNYSWHSUCZNXLF-CCEZHUSRSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36175902P | 2002-03-04 | 2002-03-04 | |
US60/361,759 | 2002-03-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2004-7013883A Division KR20050020760A (ko) | 2002-03-04 | 2003-03-04 | 말단 분화의 유도 방법 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087010088A Division KR100892016B1 (ko) | 2002-03-04 | 2003-03-04 | 말단 분화의 유도 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070057794A KR20070057794A (ko) | 2007-06-07 |
KR100868813B1 true KR100868813B1 (ko) | 2008-11-14 |
Family
ID=27805074
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077003262A KR100868813B1 (ko) | 2002-03-04 | 2003-03-04 | 말단 분화의 유도 방법 |
KR1020087010088A KR100892016B1 (ko) | 2002-03-04 | 2003-03-04 | 말단 분화의 유도 방법 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087010088A KR100892016B1 (ko) | 2002-03-04 | 2003-03-04 | 말단 분화의 유도 방법 |
Country Status (18)
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6777217B1 (en) * | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
US20040087657A1 (en) * | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
CN101259120B (zh) * | 2002-03-04 | 2012-07-04 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途 |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US20040018968A1 (en) * | 2002-04-15 | 2004-01-29 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
TW559390U (en) * | 2002-08-27 | 2003-10-21 | Molex Inc | Electrical connector |
FR2847817B1 (fr) * | 2002-11-28 | 2006-11-10 | Centre Nat Rech Scient | Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires |
US7375228B2 (en) * | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
EP1613592A4 (en) * | 2003-04-01 | 2008-03-12 | Sloan Kettering Inst Cancer | HYDROXANIC ACID COMPOUNDS AND METHOD FOR THE APPLICATION |
PL1651612T3 (pl) | 2003-07-22 | 2012-09-28 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
KR20050022216A (ko) * | 2003-08-25 | 2005-03-07 | 윤덕구 | 동결건조 즉석소면 및 그 제조방법 |
EP2201947A3 (en) * | 2003-08-26 | 2010-08-11 | Merck HDAC Research, LLC | Use of SAHA for treating mesothelioma |
US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
KR20070057822A (ko) * | 2004-08-09 | 2007-06-07 | 아스텔라스세이야쿠 가부시키가이샤 | 히스톤 디아세틸라제 (hdac) 억제제 활성을 갖는히드록시아미드 화합물 |
CA2591443A1 (en) * | 2004-12-14 | 2006-06-22 | Biorunx Co. Ltd. | Method to enhance the bone formation activity of bmp by runx2 acetylation |
JP2008524246A (ja) * | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
BRPI0606455A (pt) * | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | compostos farmacêuticos |
MX2007008810A (es) * | 2005-01-21 | 2007-11-21 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
EP1845975A1 (en) * | 2005-01-21 | 2007-10-24 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors and further antitumor agents |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
EP1855760A2 (en) | 2005-02-03 | 2007-11-21 | TopoTarget UK Limited | Combination therapies using hdac inhibitors |
AU2006226861B2 (en) | 2005-03-22 | 2012-08-16 | Dana-Farber Cancer Institute, Inc. | Treatment of protein degradation disorders |
WO2006113606A2 (en) * | 2005-04-18 | 2006-10-26 | Johns Hopkins University | Histone deacetylase inhibitors |
EP1715334A1 (fr) * | 2005-04-22 | 2006-10-25 | Adamant Technologies SA | Procédé utilisant un capteur électrochimique et électrodes formant ce capteur |
AU2006243000B2 (en) * | 2005-05-05 | 2011-05-26 | Macrophage Pharma Limited | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
JP2008540574A (ja) * | 2005-05-11 | 2008-11-20 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
KR101329437B1 (ko) * | 2005-05-13 | 2013-11-14 | 토포타겟 유케이 리미티드 | Hdac 억제제의 약학 제형 |
RU2354362C2 (ru) * | 2005-05-20 | 2009-05-10 | Мерк Энд Ко., Инк. | Композиции субероиланилид-гидроксаминовой кислоты и способы их получения |
TWI415603B (zh) | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | 1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法 |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
EP1937236A2 (en) * | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
GB0518720D0 (en) * | 2005-09-14 | 2005-10-19 | Hamlet Pharma Ab | Therapeutic combination |
WO2007117272A2 (en) * | 2005-09-30 | 2007-10-18 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Methods for treatment of hemorrhagic shock and related disorders |
WO2007056162A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
EP1954284A4 (en) * | 2005-11-04 | 2010-01-06 | Merck & Co Inc | ANTICANCER TREATMENT OF SAHA AND PEMETREXED |
WO2007056244A2 (en) * | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
JP5377968B2 (ja) * | 2005-11-10 | 2013-12-25 | トポターゲット ユーケー リミテッド | 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ(hdac)阻害剤 |
JP2009519224A (ja) * | 2005-11-18 | 2009-05-14 | グロスター ファーマシューティカルズ, インコーポレイテッド | Hdacインヒビターfk228の代謝産物誘導体 |
BRPI0619158A2 (pt) * | 2005-12-05 | 2011-09-20 | Astrazeneca Ab | processo para preparar forma que não que não seja sal de esomeprazol, composto, formulação farmacêutica, e, método de tratamento |
US20070207950A1 (en) * | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
WO2007084390A2 (en) * | 2006-01-13 | 2007-07-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
AU2007345292B2 (en) | 2006-02-14 | 2013-10-31 | Dana-Farber Cancer Institute, Inc. | Bifunctional histone deacetylase inhibitors |
BRPI0707826B1 (pt) * | 2006-02-14 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Compostos inibidores de histona desacetilase, composição farmacêutica e uso dos referidos compostos |
EP2012801A4 (en) * | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
AU2007248656B2 (en) * | 2006-05-03 | 2013-04-04 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase and tubulin deacetylase inhibitors |
JP2009536186A (ja) * | 2006-05-08 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌処置のためのジアゾール誘導体の医薬組合せ |
EP2018366A4 (en) * | 2006-05-16 | 2010-08-04 | Univ Mcgill | HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR |
US8957027B2 (en) * | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
KR20090064400A (ko) * | 2006-09-28 | 2009-06-18 | 머크 앤드 캄파니 인코포레이티드 | Hdac 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-hdac 억제제 킬레이트 착물의 약제학적 조성물 |
JP5043120B2 (ja) * | 2006-10-30 | 2012-10-10 | クロマ セラピューティクス リミテッド | ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート |
WO2008057456A2 (en) * | 2006-11-03 | 2008-05-15 | University Of Maryland, Baltimore | Methods of using saha and bortezomib for treating multiple myeloma |
WO2008083288A2 (en) * | 2006-12-29 | 2008-07-10 | Gloucester Pharmaceuticals | Purifiction of romidepsin |
AU2007342030B2 (en) * | 2006-12-29 | 2013-08-15 | Celgene Corporation | Romidepsin-based treatments for cancer |
CA2679629A1 (en) * | 2007-02-27 | 2008-09-04 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Use of histone deacetylase inhibitors for the treatment of central nervous system metastases |
EP2203421B1 (en) * | 2007-09-25 | 2014-05-07 | TopoTarget UK Limited | Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds |
KR101541436B1 (ko) * | 2007-12-20 | 2015-08-03 | 파르마 마르 에스.에이. | 항암 화합물 |
SI2262493T1 (sl) * | 2008-03-07 | 2015-07-31 | Onxeo Dk Branch Of Onxeo S.A. France | Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata |
US8440716B2 (en) | 2008-07-23 | 2013-05-14 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
EP2349985A2 (en) | 2008-10-15 | 2011-08-03 | Generics [UK] Limited | Process for the preparation of vorinostat |
WO2010061219A2 (en) | 2008-11-26 | 2010-06-03 | Generics [Uk] Limited | Polymorphs |
GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
US7994357B2 (en) * | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
ES2473792T3 (es) | 2009-04-03 | 2014-07-07 | Naturewise Biotech & Medicals Corporation | Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa |
EP2277387B1 (en) | 2009-07-22 | 2016-10-19 | NatureWise Biotech & Medicals Corporation | New use of histone deacetylase inhibitors in changing mrjp3 protein in royal jelly |
US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
JP2013508458A (ja) | 2009-10-26 | 2013-03-07 | ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド | Ftsとhdac阻害剤との組合せを用いたがん治療 |
US9238069B2 (en) | 2009-12-16 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
US20110195855A1 (en) * | 2010-02-10 | 2011-08-11 | Selinfreund Richard H | Systems and methods for improving biomarker availability |
WO2011127467A1 (en) * | 2010-04-09 | 2011-10-13 | Companion Diagnostics, Inc. | Devices, systems, and methods for biomarker stabilization |
CN103154016A (zh) | 2010-05-05 | 2013-06-12 | 特卫华妇女健康有限公司 | 使用具有逐渐降低的释放速率的单剂型减轻对象症状的方法 |
AU2011279303B2 (en) | 2010-07-12 | 2015-07-16 | Celgene Corporation | Romidepsin solid forms and uses thereof |
US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
US20130227717A1 (en) * | 2010-10-08 | 2013-08-29 | Life Sciences Research Partners Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
US20120164674A1 (en) * | 2010-10-28 | 2012-06-28 | Selinfreund Richard H | Devices and washes for biomarker stabilization |
CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
CN102793693A (zh) * | 2012-09-07 | 2012-11-28 | 天津医科大学 | 伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用 |
AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
WO2014153030A2 (en) | 2013-03-14 | 2014-09-25 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
CN103819364B (zh) * | 2014-01-24 | 2015-12-02 | 中南大学 | N-烃酰基环内酰胺衍生物的一锅合成方法 |
MX2017009532A (es) | 2015-01-23 | 2018-04-10 | Univ Temple | Uso de acidos grasos de cadena corta en prevencion de cancer. |
WO2016164392A1 (en) | 2015-04-06 | 2016-10-13 | The Johns Hopkins University | A h3t3a mutant protein efficiently reduces h3t3p and causes increased cell death of rapidly dividing cells |
CN105055386A (zh) * | 2015-08-12 | 2015-11-18 | 天津医科大学总医院 | 伏立诺他用于制备免疫调节药物的应用 |
CN106187818B (zh) * | 2016-06-27 | 2017-12-08 | 刘美新 | 一种制备抗癌药物伏立诺他的方法 |
US11065217B2 (en) | 2017-01-27 | 2021-07-20 | Temple University—Of the Commonwealth System of Higher Education | Use of short chain fatty acids for the treatment and prevention of diseases and disorders |
JP7136807B2 (ja) | 2017-04-17 | 2022-09-13 | ザ・ユニバーシティ・オブ・シカゴ | ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料 |
CN114846012B (zh) | 2019-09-27 | 2024-01-26 | 武田药品工业株式会社 | 可用作hdac6抑制剂的2-异吲哚-1,3,4-噁二唑衍生物 |
US11583521B2 (en) * | 2020-07-01 | 2023-02-21 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995031977A1 (en) * | 1994-05-19 | 1995-11-30 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of terminal differentiation and methods of use thereof |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA622801A (en) | 1961-06-27 | L. Clark Robert | Substituted benzimidazolones | |
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
DE2460689C3 (de) * | 1974-12-20 | 1980-06-26 | Klinge Pharma Gmbh & Co, 8000 Muenchen | 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
JPS61251649A (ja) * | 1985-04-05 | 1986-11-08 | Mitsubishi Petrochem Co Ltd | ジカルボン酸ジアニリドの製造法 |
US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5608108A (en) * | 1988-11-14 | 1997-03-04 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and method of use thereof |
US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
USRE38506E1 (en) * | 1991-10-04 | 2004-04-20 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5369108A (en) * | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
JPH11514857A (ja) | 1995-09-20 | 1999-12-21 | メルク エンド カンパニー インコーポレーテッド | 抗原虫剤の標的としてのヒストンデアセチラーゼ |
US6239178B1 (en) * | 1996-05-17 | 2001-05-29 | George Dimelow Alexander Lord | Method of treating mammals |
US6043389A (en) * | 1997-03-11 | 2000-03-28 | Mor Research Applications, Ltd. | Hydroxy and ether-containing oxyalkylene esters and uses thereof |
US6124495A (en) | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
JPH10262694A (ja) | 1997-03-28 | 1998-10-06 | Sumitomo Forestry Co Ltd | B細胞性リンパ腫の骨髄転移検査法 |
US6387673B1 (en) | 1997-05-01 | 2002-05-14 | The Salk Institute For Biological Studies | Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds |
US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
HU226044B1 (en) | 1998-01-30 | 2008-03-28 | Univ New York | Use of inhibitors of the lymhotoxin (lt) pathway to prepare pharmaceutical compositions for treatment of follicular lymphomas |
AUPP505798A0 (en) | 1998-08-04 | 1998-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound fr225497 substance |
EE200100187A (et) | 1998-09-25 | 2002-08-15 | Warner-Lambert Company | Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga |
JP2002527449A (ja) | 1998-10-13 | 2002-08-27 | 藤沢薬品工業株式会社 | 環状テトラペプチド化合物およびその用途 |
EP1173562A2 (en) | 1999-05-03 | 2002-01-23 | Methylgene, Inc. | Inhibition of histone deacetylase |
US6450992B1 (en) | 1999-07-02 | 2002-09-17 | Smith & Nephew, Inc. | Cannula interface |
JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
CN1378450A (zh) * | 1999-09-08 | 2002-11-06 | 斯隆-凯特林癌症研究院 | 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法 |
US6673564B2 (en) | 1999-10-18 | 2004-01-06 | Millennium Pharmaceuticals, Inc. | Methods for using 22045, a human cyclic nucleotide phosphodiesterase |
EP1233958B1 (en) * | 1999-11-23 | 2011-06-29 | MethylGene Inc. | Inhibitors of histone deacetylase |
AU2001248701A1 (en) * | 2000-03-24 | 2001-10-03 | Methylgene, Inc. | Inhibitors of histone deacetylase |
AU2001285042A1 (en) | 2000-08-18 | 2002-03-04 | The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US20050004007A1 (en) * | 2000-09-12 | 2005-01-06 | Steven Grant | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents |
GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
EP2292593A3 (en) | 2000-09-29 | 2011-05-25 | TopoTarget UK Limited | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
AR035659A1 (es) | 2000-12-07 | 2004-06-23 | Hoffmann La Roche | Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos |
US6533803B2 (en) * | 2000-12-22 | 2003-03-18 | Advanced Medical Applications, Inc. | Wound treatment method and device with combination of ultrasound and laser energy |
US20020183388A1 (en) * | 2001-02-01 | 2002-12-05 | Gudas Lorraine J. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
US6495719B2 (en) * | 2001-03-27 | 2002-12-17 | Circagen Pharmaceutical | Histone deacetylase inhibitors |
US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
US7199227B2 (en) * | 2001-06-14 | 2007-04-03 | Bristol-Myers Squibb Company | Polynucleotides encoding human histone deacetylase HDAC9c |
ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
US20040087657A1 (en) | 2001-10-16 | 2004-05-06 | Richon Victoria M. | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
US20040132643A1 (en) * | 2002-01-09 | 2004-07-08 | Fojo Antonio Tito | Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms |
US20030235588A1 (en) * | 2002-02-15 | 2003-12-25 | Richon Victoria M. | Method of treating TRX mediated diseases |
US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
CN101259120B (zh) * | 2002-03-04 | 2012-07-04 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸或其可药用盐在制备诱导末期分化的药物的用途 |
US20040018968A1 (en) | 2002-04-15 | 2004-01-29 | George Sgouros | Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
WO2004046104A2 (en) * | 2002-11-20 | 2004-06-03 | Errant Gene Therapeutics, Llc | Treatment of lung cells with histone deacetylase inhibitors |
EP1613592A4 (en) * | 2003-04-01 | 2008-03-12 | Sloan Kettering Inst Cancer | HYDROXANIC ACID COMPOUNDS AND METHOD FOR THE APPLICATION |
EP2201947A3 (en) | 2003-08-26 | 2010-08-11 | Merck HDAC Research, LLC | Use of SAHA for treating mesothelioma |
CN101856348A (zh) * | 2003-08-29 | 2010-10-13 | 斯隆-凯特林癌症研究所 | 联合治疗癌症的方法 |
AU2006279400A1 (en) | 2005-08-18 | 2007-02-22 | Merck & Co. Inc. | Combination methods of SAHA and Targretin for treating cancer |
WO2007056162A2 (en) | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
WO2007056244A2 (en) | 2005-11-04 | 2007-05-18 | Merck & Co., Inc. | Methods of using saha and erlotinib for treating cancer |
EP1954284A4 (en) | 2005-11-04 | 2010-01-06 | Merck & Co Inc | ANTICANCER TREATMENT OF SAHA AND PEMETREXED |
-
2003
- 2003-03-04 CN CN2008100838935A patent/CN101259120B/zh not_active Expired - Lifetime
- 2003-03-04 KR KR1020077003262A patent/KR100868813B1/ko active IP Right Grant
- 2003-03-04 EP EP20100184834 patent/EP2266552A3/en not_active Withdrawn
- 2003-03-04 ES ES09005103.8T patent/ES2532607T3/es not_active Expired - Lifetime
- 2003-03-04 KR KR1020087010088A patent/KR100892016B1/ko active IP Right Grant
- 2003-03-04 AU AU2003213684A patent/AU2003213684C1/en active Active
- 2003-03-04 RU RU2004133675A patent/RU2320331C2/ru active Protection Beyond IP Right Term
- 2003-03-04 NZ NZ55018503A patent/NZ550185A/xx not_active IP Right Cessation
- 2003-03-04 CA CA2671976A patent/CA2671976C/en not_active Expired - Lifetime
- 2003-03-04 NZ NZ535578A patent/NZ535578A/en not_active IP Right Cessation
- 2003-03-04 MX MXPA04008577A patent/MXPA04008577A/es active IP Right Grant
- 2003-03-04 EP EP20090005103 patent/EP2082737B1/en not_active Expired - Lifetime
- 2003-03-04 CN CN2013102683183A patent/CN103393630A/zh active Pending
- 2003-03-04 EP EP03711372A patent/EP1487426B1/en not_active Revoked
- 2003-03-04 BR BR0308250A patent/BR0308250A/pt not_active Application Discontinuation
- 2003-03-04 US US10/379,149 patent/US20040072735A1/en not_active Abandoned
- 2003-03-04 JP JP2003574115A patent/JP4732693B2/ja not_active Expired - Lifetime
- 2003-03-04 IL IL16390903A patent/IL163909A0/xx unknown
- 2003-03-04 WO PCT/US2003/006451 patent/WO2003075839A2/en active IP Right Grant
- 2003-03-04 CA CA 2478094 patent/CA2478094C/en not_active Expired - Lifetime
- 2003-03-04 PL PL37223903A patent/PL372239A1/xx unknown
- 2003-03-04 NZ NZ567758A patent/NZ567758A/en not_active IP Right Cessation
- 2003-03-04 EP EP20100183586 patent/EP2322160A1/en not_active Withdrawn
- 2003-03-04 RU RU2007112879A patent/RU2394022C2/ru active
- 2003-03-04 CA CA 2632078 patent/CA2632078C/en not_active Expired - Lifetime
- 2003-03-04 CN CNA038095890A patent/CN1720034A/zh active Pending
- 2003-07-09 US US10/616,649 patent/US7399787B2/en active Active
- 2003-09-16 US US10/665,079 patent/US20040127523A1/en not_active Abandoned
-
2004
- 2004-03-01 ZA ZA200407942A patent/ZA200407942B/xx unknown
- 2004-09-05 IL IL16390904A patent/IL163909A/en not_active IP Right Cessation
- 2004-09-28 NO NO20044112A patent/NO329984B1/no not_active IP Right Cessation
-
2005
- 2005-05-25 HK HK05104380A patent/HK1072362A1/xx not_active IP Right Cessation
-
2006
- 2006-02-23 ZA ZA200601757A patent/ZA200601757B/en unknown
-
2007
- 2007-09-11 US US11/853,700 patent/US7732490B2/en active Active
- 2007-11-09 US US11/983,469 patent/US20080114069A1/en not_active Abandoned
-
2009
- 2009-03-12 IL IL197582A patent/IL197582A/en active IP Right Grant
- 2009-07-20 NO NO20092714A patent/NO332749B1/no not_active IP Right Cessation
- 2009-08-17 JP JP2009188710A patent/JP5586896B2/ja not_active Expired - Lifetime
- 2009-08-17 JP JP2009188712A patent/JP5675071B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-09 RU RU2010108448/15A patent/RU2530648C2/ru active
- 2010-04-23 US US12/799,368 patent/US8067472B2/en not_active Expired - Fee Related
-
2011
- 2011-10-19 US US13/276,710 patent/US20120041067A1/en not_active Abandoned
-
2014
- 2014-07-17 JP JP2014146512A patent/JP2014237669A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995031977A1 (en) * | 1994-05-19 | 1995-11-30 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of terminal differentiation and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100868813B1 (ko) | 말단 분화의 유도 방법 | |
US7375137B2 (en) | Methods of treating cancer with HDAC inhibitors | |
US8101663B2 (en) | Polymorphs of suberoylanilide hydroxamic acid | |
US20090012175A1 (en) | Methods of treating cancer with HDAC inhibitors | |
KR20050020760A (ko) | 말단 분화의 유도 방법 | |
Richon et al. | Methods of treating Hodgkin's and non-Hodgkin's lymphoma | |
NZ568678A (en) | Methods of inducing terminal differentiation using suberoylanilide hydroxamic acid (SAHA) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
N231 | Notification of change of applicant | ||
N231 | Notification of change of applicant | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121024 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131024 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141224 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170929 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 12 |